Roche struck a strategic collaboration and license deal with Manifold Bio to develop next-generation 'brain shuttle' technologies for neurological diseases. The pact includes an upfront payment reported at $55 million and potential milestones, giving Roche access to Manifold’s AI-driven discovery platform to engineer vehicles that ferry therapeutics across the blood-brain barrier. Roche intends to deploy the technology to improve CNS delivery as it advances late-stage neurology candidates. The agreement signals big pharma’s continued hunt for robust delivery mechanisms to overcome CNS access limits and accelerate development of biologics for brain disorders.